Olmesartan/Hydrochlorothiazid Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Hydrochlorothiazid Aurobindo, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension in adults, often in combination with a diuretic. GNH USA supplies Olmesartan/Hydrochlorothiazid Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan/Hydrochlorothiazid Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Hydrochlorothiazide is a combined antihypertensive agent that lowers blood pressure through dual mechanisms.

- Hypertension: Improves blood pressure control when monotherapy is insufficient. - Heart failure: Assists in managing fluid overload as part of a broader regimen. - Diabetic nephropathy: Helps reduce proteinuria and protect renal function in patients with type 2 diabetes. - Stroke prevention: Contributes to secondary prevention of cerebrovascular events in hypertensive patients. - Chronic kidney disease: Supports blood pressure reduction to slow disease progression. - Post‑myocardial infarction: Aids in long‑term blood pressure management after an MI.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache. - Fatigue. - Increased urination. - Electrolyte disturbances such as low potassium. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension. - Acute kidney injury. - Hyperkalemia. - Angio‑edema involving the face, lips or tongue. - Pancreatitis. - Severe skin reactions such as Stevens‑Johnson syndrome.

Patients should be monitored for blood pressure response and renal function during therapy.

- Pregnancy: Contraindicated in the second and third trimesters due to fetal toxicity risk. - Breastfeeding: Use only if the benefit outweighs potential risk to the infant. - Electrolyte monitoring: Check serum potassium and sodium regularly. - Renal impairment: Dose adjustment may be required; monitor creatinine. - Drug interactions: Review concomitant medications for additive hypotensive effects. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment. - Potassium‑rich supplements or potassium‑sparing diuretics (risk of hyperkalemia). - NSAIDs (may blunt antihypertensive effect and affect renal function).

Moderate Interactions (Monitor Closely): - Lithium (increased lithium levels). - Antidiabetic agents (enhanced hypoglycaemic effect). - ACE inhibitors or other ARBs (additive risk of hyperkalemia and renal dysfunction).